Methods for treating HCV
DCFirst Claim
Patent Images
1. A method of treatment for HCV, comprising administering at least two direct acting antiviral agents (DAAs) to an HCV treatment-naï
- ve patient infected with HCV genotype 1, wherein said treatment does not include administration of either interferon or ribavirin to said patient, and said treatment lasts for 8 weeks, wherein said at least two DAAs comprise
0 Assignments
Litigations
0 Petitions
Accused Products
Abstract
The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).
201 Citations
20 Claims
-
1. A method of treatment for HCV, comprising administering at least two direct acting antiviral agents (DAAs) to an HCV treatment-naï
- ve patient infected with HCV genotype 1, wherein said treatment does not include administration of either interferon or ribavirin to said patient, and said treatment lasts for 8 weeks, wherein said at least two DAAs comprise
- View Dependent Claims (2, 3, 4, 5)
-
6. A method of treatment for HCV, comprising administering at least two direct acting antiviral agents (DAAs) to an HCV treatment-naï
- ve patient infected with HCV genotype 1, wherein said treatment does not include administration of either interferon or ribavirin to said patient, and said treatment lasts for 8 weeks, and wherein said at least two DAAs comprise PSI-7977 and GS-5885.
- View Dependent Claims (7, 8, 9, 10, 11)
-
12. A method of treatment for HCV, comprising administering at least two direct acting antiviral agents (DAAs) to an HCV treatment-naï
- ve patient infected with HCV genotype 1, wherein said treatment does not include administration of either interferon or ribavirin to said patient, and said treatment lasts for 8, 9, 10, 11 or 12 weeks, and wherein said at least two DAAs comprise Compound 1, Compound 2 and Compound 4, or said at least two DAAs comprise PSI-7977 and GS-5885.
- View Dependent Claims (13, 14, 15, 16, 17, 18, 19, 20)
Specification